NO2525817T3 - - Google Patents
Info
- Publication number
- NO2525817T3 NO2525817T3 NO11735230A NO11735230A NO2525817T3 NO 2525817 T3 NO2525817 T3 NO 2525817T3 NO 11735230 A NO11735230 A NO 11735230A NO 11735230 A NO11735230 A NO 11735230A NO 2525817 T3 NO2525817 T3 NO 2525817T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29709810P | 2010-01-21 | 2010-01-21 | |
| PCT/US2011/022062 WO2011091255A1 (en) | 2010-01-21 | 2011-01-21 | Vaccine vectors and methods of enhancing immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2525817T3 true NO2525817T3 (no) | 2018-01-06 |
Family
ID=44307229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11735230A NO2525817T3 (no) | 2010-01-21 | 2011-01-21 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8956618B2 (no) |
| EP (1) | EP2525817B8 (no) |
| JP (3) | JP6242050B2 (no) |
| KR (1) | KR101638661B1 (no) |
| CN (1) | CN102811734B (no) |
| AU (1) | AU2011207331C1 (no) |
| CA (1) | CA2787661C (no) |
| CL (1) | CL2012002016A1 (no) |
| CO (1) | CO6561819A2 (no) |
| DK (1) | DK2525817T3 (no) |
| EA (1) | EA023058B1 (no) |
| ES (1) | ES2643646T3 (no) |
| HU (1) | HUE037157T2 (no) |
| MX (1) | MX341775B (no) |
| NO (1) | NO2525817T3 (no) |
| NZ (1) | NZ601609A (no) |
| PL (1) | PL2525817T3 (no) |
| PT (1) | PT2525817T (no) |
| UA (1) | UA110024C2 (no) |
| WO (1) | WO2011091255A1 (no) |
| ZA (1) | ZA201205824B (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2214701T3 (pl) * | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| UA110024C2 (uk) | 2010-01-21 | 2015-11-10 | Вакцинний вектор і спосіб посилення імунної відповіді | |
| KR102007132B1 (ko) * | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
| WO2012072788A1 (en) | 2010-12-02 | 2012-06-07 | Mab-Factory Gmbh | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
| NZ711019A (en) * | 2013-02-14 | 2019-07-26 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| EP2968423A4 (en) | 2013-03-15 | 2016-11-09 | Univ Arkansas | COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES |
| CN105399808B (zh) * | 2015-11-23 | 2019-05-10 | 青岛农业大学 | 一种许氏平鮋免疫增强蛋白hmgb1基因及编码蛋白和应用 |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
| US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
| US12048734B2 (en) | 2020-04-17 | 2024-07-30 | Op-T Llc | Bioactive peptides and methods of use thereof |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100240182B1 (ko) | 1991-03-05 | 2000-01-15 | 레슬리 제인 에드워즈 | 재조합 단백질을 발헨하는 약독해진 박테리아를 함유하는 백신 |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| DK0822199T3 (da) | 1991-10-25 | 2004-12-27 | Amgen Inc | N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| DE69322092T2 (de) | 1992-09-04 | 1999-07-15 | University Of Saskatchewan, Saskatoon | Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien |
| AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| JP3657271B2 (ja) | 1995-03-01 | 2005-06-08 | イミュネックス・コーポレーション | 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物 |
| AU693713B2 (en) | 1995-06-07 | 1998-07-02 | Immunex Corporation | CD40L mutein |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| CA2313805A1 (en) | 1997-12-19 | 1999-07-01 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
| GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| EP1108034B1 (en) | 1998-09-04 | 2008-08-06 | Emergent Product Development UK Limited | Attenuated salmonella spi2 mutants as antigen carriers |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| MXPA00012796A (es) | 1999-12-28 | 2002-05-23 | Akzo Nobel Nv | Vacuna de salmonella. |
| EP1255560B1 (en) | 2000-02-02 | 2008-10-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE | Cd40 ligand adjuvant for respiratory syncytial virus vaccine |
| ATE300949T1 (de) | 2000-03-17 | 2005-08-15 | Pharmacia & Upjohn Co Llc | Ssa inaktivierte salmonella impfstoffe |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| WO2002000232A2 (en) * | 2000-06-26 | 2002-01-03 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| SK15422003A3 (sk) | 2001-05-15 | 2005-01-03 | Research Institute North Shore-Long Island Jewish | Použitie fragmentov HMG ako protizápalových činidiel |
| EP2687593A1 (en) | 2001-05-15 | 2014-01-22 | Ortho-McNeil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| CA2470640A1 (en) | 2001-12-19 | 2003-06-26 | Alcedo Biotech Gmbh | Use of hmgb proteins and nucleic acids that code therefor |
| US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| EP1499191B1 (en) | 2002-04-15 | 2012-05-09 | Washington University in St. Louis | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20060121047A1 (en) | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
| US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| NZ540067A (en) | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
| US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
| US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| WO2005058950A2 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| JP2008508855A (ja) | 2004-04-27 | 2008-03-27 | インターツェル・アクチェンゲゼルシャフト | Ｔｄ抗原 |
| WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
| EP1768698A4 (en) * | 2004-06-17 | 2009-01-28 | Medimmune Inc | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES |
| WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| CN101080487B (zh) | 2004-10-07 | 2012-11-14 | 阿戈斯治疗公司 | 成熟树突细胞组合物及其培养方法 |
| GB0423681D0 (en) | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| CA2593746A1 (en) | 2004-12-21 | 2006-06-29 | Vaxinnate Corporation | Compositions of influenza viral proteins and methods of use thereof |
| WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
| US20060286074A1 (en) | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| EP1909834A2 (en) | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| JP2009511452A (ja) | 2005-10-07 | 2009-03-19 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ |
| EP1951862B1 (en) | 2005-11-07 | 2013-07-24 | MicroVAX, LLC | Cd40 ligand fusion protein vaccine |
| WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
| WO2007130725A2 (en) | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
| WO2008094197A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| US8564612B2 (en) * | 2006-08-04 | 2013-10-22 | Apple Inc. | Deep pixel pipeline |
| CN104278014A (zh) * | 2006-08-09 | 2015-01-14 | 米迪缪尼有限公司 | 流感血凝素和神经氨酸酶变体 |
| CN101522210B (zh) * | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | 增强免疫应答的组合物和方法 |
| WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| AU2008275513A1 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
| NZ585776A (en) | 2007-10-30 | 2012-07-27 | Univ Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PL2214701T3 (pl) | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| UA110024C2 (uk) | 2010-01-21 | 2015-11-10 | Вакцинний вектор і спосіб посилення імунної відповіді | |
| KR102007132B1 (ko) | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
| MX2014005754A (es) | 2011-11-11 | 2015-02-10 | Nutrition Physiology Company Llc | Bacterias de ácido láctico y su uso como suplementos dietéticos para aves de corral. |
-
2011
- 2011-01-21 UA UAA201210026A patent/UA110024C2/ru unknown
- 2011-01-21 EA EA201290675A patent/EA023058B1/ru not_active IP Right Cessation
- 2011-01-21 US US13/574,504 patent/US8956618B2/en active Active
- 2011-01-21 ES ES11735230.2T patent/ES2643646T3/es active Active
- 2011-01-21 AU AU2011207331A patent/AU2011207331C1/en active Active
- 2011-01-21 KR KR1020127021697A patent/KR101638661B1/ko active IP Right Grant
- 2011-01-21 CA CA2787661A patent/CA2787661C/en active Active
- 2011-01-21 MX MX2012008506A patent/MX341775B/es active IP Right Grant
- 2011-01-21 HU HUE11735230A patent/HUE037157T2/hu unknown
- 2011-01-21 WO PCT/US2011/022062 patent/WO2011091255A1/en active Application Filing
- 2011-01-21 JP JP2012550153A patent/JP6242050B2/ja active Active
- 2011-01-21 DK DK11735230.2T patent/DK2525817T3/en active
- 2011-01-21 EP EP11735230.2A patent/EP2525817B8/en active Active
- 2011-01-21 NZ NZ601609A patent/NZ601609A/en unknown
- 2011-01-21 CN CN201180006369.8A patent/CN102811734B/zh active Active
- 2011-01-21 PL PL11735230T patent/PL2525817T3/pl unknown
- 2011-01-21 PT PT117352302T patent/PT2525817T/pt unknown
- 2011-01-21 NO NO11735230A patent/NO2525817T3/no unknown
-
2012
- 2012-07-19 CO CO12122137A patent/CO6561819A2/es not_active Application Discontinuation
- 2012-07-20 CL CL2012002016A patent/CL2012002016A1/es unknown
- 2012-08-02 ZA ZA2012/05824A patent/ZA201205824B/en unknown
-
2015
- 2015-02-16 US US14/623,105 patent/US9913893B2/en active Active
-
2016
- 2016-03-08 JP JP2016044306A patent/JP2016117757A/ja active Pending
-
2017
- 2017-12-05 JP JP2017233454A patent/JP6687585B2/ja active Active